Phase 2, randomized, double-blind, placebo-controlled multi-center trial of the clinical and biological effects of anti-CD14 treatment in hospitalized patients with COVID-19 pneumonia

BACKGROUND: Severe COVID-19 is associated with innate immunopathology, and CD14, a proximal activator of innate immunity, has been suggested as a potential therapeutic target. METHODS: We conducted the COVID-19 anti-CD14 Treatment Trial (CaTT), a Phase II randomized, double-blind, placebo-controlled...

Descripción completa

Detalles Bibliográficos
Autores principales: Mabrey, F. Linzee, Nian, Hui, Yu, Chang, Barnes, Elizabeth M., Malhotra, Uma, Mikacenic, Carmen, Goldstein, Julia, O'Mahony, D. Shane, Garcia-Diaz, Julia, Finn, Patricia, Voelker, Kirk, Morrell, Eric D., Self, Wesley H., Becker, Patrice M., Martin, Thomas R., Wurfel, Mark M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276526/
https://www.ncbi.nlm.nih.gov/pubmed/37336058
http://dx.doi.org/10.1016/j.ebiom.2023.104667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276526/
https://www.ncbi.nlm.nih.gov/pubmed/37336058
http://dx.doi.org/10.1016/j.ebiom.2023.104667

Ejemplares similares